Risdiplam trials: exciting early results in Firefish – TreatSMA
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Interim results: Infantile-onset SMA | SPINRAZA® (nusinersen) HCP
Ionis's Spinraza Still Bests Novartis's Zolgensma (NYSE:NVS) | Seeking Alpha
Higher-dose Spinraza SMA Trial Now Enrolls After No Safety Issues Found
Threats to Spinraza are mounting, but Biogen still has cards to play | Evaluate
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Drug Trials Snapshots: SPINRAZA | FDA
New Results From Landmark NURTURE Study Show That
From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1 - Pediatric Neurology
Therapeutic approaches for spinal muscular atrophy (SMA) | Gene Therapy
Spinraza – Canada – final drug review | High, apple pie, in the sky, hopes
Drug Trials Snapshots: SPINRAZA | FDA
SMA treatment: Novartis and Biogen face lost market opportunities
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Biogen Announces New Spinraza Data Ahead of Presentation | BioSpace
Frontiers | Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment | Pharmacology
Biogen and Ionis Pharmaceuticals: A Message to the SMA Community - Muscular Dystrophy Association
Spinraza Can Restore Motor Function in Children With Late-Onset SMA, Study Finds
SPINRAZA® (nusinersen) Safety Profile | HCP
Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA) - Clinical Trials Arena
